Who are FOLFIRINOX treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PTH followed by dose dense AC of FEC, Carboplatin, Etoposide, Ifosfamide, CEV chemotherapy, Adjuvant chemotherapy, FLOT, TCH chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folfirinox-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

FOLFIRINOX treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FOLFIRINOX treatment (FOLFIRINOX treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy regimen. Area: Oncology.

phase 2 chemotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

FOLFIRINOX treatment (FOLFIRINOX treatment) — Centre Georges Francois Leclerc. FOLFIRINOX is a chemotherapy regimen that combines four different drugs to target rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FOLFIRINOX treatment TARGET	FOLFIRINOX treatment	Centre Georges Francois Leclerc	phase 2	chemotherapy regimen
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)
Carboplatin, Etoposide, Ifosfamide	Carboplatin, Etoposide, Ifosfamide	University Hospital Muenster	marketed	Combination chemotherapy regimen	DNA (multiple mechanisms: alkylation, cross-linking, topoisomerase II inhibition)
CEV chemotherapy	CEV chemotherapy	Sun Yat-sen University	marketed	Combination chemotherapy regimen
Adjuvant chemotherapy	Adjuvant chemotherapy	Institut de Cancérologie de Lorraine	marketed	Chemotherapy regimen (multi-agent or single-agent cytotoxic)
FLOT	FLOT	European Organisation for Research and Treatment of Cancer - EORTC	marketed	Chemotherapy regimen (combination)
TCH chemotherapy	TCH chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)	HER2, microtubule, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy regimen class)

University Hospital, Grenoble · 2 drugs in this class
Canadian Cancer Trials Group · 1 drug in this class
Centre Georges Francois Leclerc · 1 drug in this class
Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. · 1 drug in this class
French Innovative Leukemia Organisation · 1 drug in this class
AIO-Studien-gGmbH · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
National Research Center for Hematology, Russia · 1 drug in this class
Ospedale Santa Croce-Carle Cuneo · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FOLFIRINOX treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/folfirinox-treatment. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing